Resistance to targeted cancer therapies remains a major clinical challenge. But what if antibodies could be engineered to recognize the very mutations that allow tumor cells to escape treatment?
In a collaboration between the University of Stuttgart, TU Braunschweig and YUMAB, researchers developed a novel human EGFR antibody that combines high affinity with the ability to recognize clinically relevant EGFR escape mutations.
Discover the science behind this approach in our latest Literature Digest: